#BEGIN_DRUGCARD DB02967

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
128-53-0

# ChEBI_ID:
7269

# Chemical_Formula:
C6H7NO2

# Chemical_IUPAC_Name:
1-ethyl-2,5-dihydro-1H-pyrrole-2,5-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A sulfhydryl reagent that is widely used in experimental biochemical studies. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Enzyme Inhibitors
Sulfhydryl Reagents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
N-Ethylmaleimide

# HET_ID:
NEQ

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H7NO2/c1-2-7-5(8)3-4-6(7)9/h3-4H,2H2,1H3

# InChI_Key:
InChIKey=HDFGOPSGAURCEO-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C02441

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2967

# Mechanism_Of_Action:
Not Available

# Melting_Point:
45.5 Â°C

# Molecular_Weight_Avg:
125.1253

# Molecular_Weight_Mono:
125.047678473

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1G86

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.02

# Predicted_LogS:
0.31

# Predicted_Water_Solubility:
2.54e+02 g/l

# Primary_Accession_No:
DB02967

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4362

# PubChem_Substance_ID:
46509138

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02327

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCN1C(=O)C=CC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:42 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Note=Localized in granules from where it may be secreted or transported to other locations in the ce

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CLC

# Drug_Target_1_GenBank_ID_Gene:
L01664

# Drug_Target_1_GenBank_ID_Protein:
187274

# Drug_Target_1_GeneCard_ID:
CLC

# Drug_Target_1_Gene_Name:
CLC

# Drug_Target_1_Gene_Sequence:
>429 bp
ATGTCCCTGCTACCCGTGCCATACACAGAGGCTGCCTCTTTGTCTACTGGTTCTACTGTG
ACAATCAAAGGGCGACCACTTGTCTGTTTCTTGAATGAACCATATCTGCAGGTGGATTTC
CACACTGAGATGAAGGAGGAATCAGACATTGTCTTCCATTTCCAAGTGTGCTTTGGTCGT
CGTGTGGTCATGAACAGCCGTGAGTATGGGGCCTGGAAGCAGCAGGTGGAATCCAAGAAC
ATGCCCTTTCAGGATGGCCAAGAATTTGAACTGAGCATCTCAGTGCTGCCAGATAAGTAC
CAGGTAATGGTCAATGGCCAATCCTCTTACACCTTTGACCATAGAATCAAGCCTGAGGCT
GTGAAGATGGTGCAAGTGTGGAGAGATATCTCCCTGACCAAATTTAATGTCAGCTATTTA
AAGAGATAA

# Drug_Target_1_General_Function:
Involved in sugar binding

# Drug_Target_1_General_References:
10529229	Swaminathan GJ, Leonidas DD, Savage MP, Ackerman SJ, Acharya KR: Selective recognition of mannose by the human eosinophil Charcot-Leyden crystal protein (galectin-10): a crystallographic study at 1.8 A resolution. Biochemistry. 1999 Oct 19;38(42):13837-43.
1577491	Mastrianni DM, Eddy RL, Rosenberg HF, Corrette SE, Shows TB, Tenen DG, Ackerman SJ: Localization of the human eosinophil Charcot-Leyden crystal protein (lysophospholipase) gene (CLC) to chromosome 19 and the human ribonuclease 2 (eosinophil-derived neurotoxin) and ribonuclease 3 (eosinophil cationic protein) genes (RNS2 and RNS3) to chromosome 14. Genomics. 1992 May;13(1):240-2.
8419478	Ackerman SJ, Corrette SE, Rosenberg HF, Bennett JC, Mastrianni DM, Nicholson-Weller A, Weller PF, Chin DT, Tenen DG: Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. J Immunol. 1993 Jan 15;150(2):456-68.
8747464	Leonidas DD, Elbert BL, Zhou Z, Leffler H, Ackerman SJ, Acharya KR: Crystal structure of human Charcot-Leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate-binding family of galectins. Structure. 1995 Dec 15;3(12):1379-93.
9119387	Dyer KD, Handen JS, Rosenberg HF: The genomic structure of the human Charcot-Leyden crystal protein gene is analogous to those of the galectin genes. Genomics. 1997 Mar 1;40(2):217-21.

# Drug_Target_1_HGNC_ID:
HGNC:2014

# Drug_Target_1_HPRD_ID:
08351

# Drug_Target_1_ID:
3437

# Drug_Target_1_Locus:
19q13.1

# Drug_Target_1_Molecular_Weight:
16481

# Drug_Target_1_Name:
Eosinophil lysophospholipase

# Drug_Target_1_Number_of_Residues:
142

# Drug_Target_1_PDB_ID:
1QKQ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00337	Gal-bind_lectin

# Drug_Target_1_Protein_Sequence:
>Eosinophil lysophospholipase
MSLLPVPYTEAASLSTGSTVTIKGRPLVCFLNEPYLQVDFHTEMKEESDIVFHFQVCFGR
RVVMNSREYGAWKQQVESKNMPFQDGQEFELSISVLPDKYQVMVNGQSSYTFDHRIKPEA
VKMVQVWRDISLTKFNVSYLKR

# Drug_Target_1_Reaction:
2-lysophosphatidylcholine + H2O = glycerophosphocholine + a carboxylate ALL_REAC (other) R01309 R02744 R02746 R02747 R03416 R03417 R04499

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
May have both lysophospholipase and carbohydrate-binding activities

# Drug_Target_1_SwissProt_ID:
Q05315

# Drug_Target_1_SwissProt_Name:
LPPL_HUMAN

# Drug_Target_1_Synonyms:
CLC
Charcot-Leyden crystal protein
EC 3.1.1.5
Galectin-10
Lysolecithin acylhydrolase

# Drug_Target_1_Theoretical_pI:
7.50

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02967
